Standout Papers
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. (1998)
- Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study (2017)
- Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin’s Lymphoma: Safety and Efficacy of Re-Treatment (2000)
- Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study (2015)
Immediate Impact
8 by Nobel laureates 5 from Science/Nature 96 standout
Citing Papers
CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial
2024 Standout
Works of Brian K. Link being referenced
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
2017 Standout
Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia
2011
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Brian K. Link | 7068 | 5480 | 3400 | 275 | 10.9k | |
| Myron S. Czuczman | 6364 | 4528 | 3384 | 239 | 10.2k | |
| Jonathan W. Friedberg | 8916 | 6334 | 3744 | 392 | 12.3k | |
| Philippe Solal‐Céligny | 4447 | 4261 | 2634 | 108 | 8.5k | |
| Anton Hagenbeek | 11213 | 7618 | 4149 | 257 | 16.0k | |
| Luis Fayad | 6166 | 5377 | 2647 | 325 | 9.5k | |
| Massimo Federico | 7852 | 5384 | 2000 | 281 | 11.7k | |
| Kensei Tobinai | 7148 | 5704 | 2342 | 422 | 13.3k | |
| Michele Ghielmini | 6279 | 4442 | 2971 | 134 | 8.6k | |
| Stephen J. Schuster | 4598 | 8021 | 1959 | 364 | 11.4k | |
| Catherine Thiéblemont | 9600 | 6772 | 4215 | 406 | 13.8k |
All Works
Login with ORCID to disown or claim papers
Loading papers...